# Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

> **NCT06008119** · PHASE3 · RECRUITING · sponsor: **Shanghai Kechow Pharma, Inc.** · enrollment: 165 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** Tunlametinib plus Vemurafenib
- **DRUG:** Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab

## Key facts

- **NCT ID:** NCT06008119
- **Lead sponsor:** Shanghai Kechow Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-25
- **Primary completion:** 2026-12-24
- **Final completion:** 2026-12-24
- **Target enrollment:** 165 (ESTIMATED)
- **Last updated:** 2025-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06008119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06008119, "Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06008119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*